Grace Therapeutics Inc (GRCE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.78-1.66%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · GRCE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
GRCE — earnings miss
Dated 2026-08-13
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 “Results of Operations and Financial Condition.” On August 13, 2026, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for…
Why it matters: The company reported $3.2 million in quarterly cash use and says cash lasts through 2028. Higher use could weaken that runway.
Worry ifThe next report shows cash used in operations above $3.2 million for the quarter.
Less concerning ifThe next report shows cash used in operations at or below $3.2 million for the quarter.
Why it matters: Management says plant readiness will set the resubmission timing. A clear path would show progress; a delay would add time to the FDA process.
Watch forOn November 12, management names a ready plant and gives a plan to resubmit. The plan is tied to FDA and data milestones.
Also watch forOn November 12, management says neither plant is ready or the plan to resubmit has slipped.
Why it matters: The current plant could support an earlier NDA resubmission. FDA clearance would remove a key hurdle.
Supportive ifThe company reports that the plant fixed its cGMP issues and the FDA confirms it is ready after reinspection.
Worry ifThe FDA keeps the plant out of compliance, or another inspection finds unresolved cGMP issues.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$146 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $526 loss on $10,000 · 5.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,472 loss on $10,000 · 64.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.